KOREA WHO
-
-
-
CEO of Samsung Epis Holdings and Samsung Bioepis
Kim Kyung-ah
Samsung’s First Female CEO From Biosimilar Research Leads Epis Holdings
-
Last Updated on Dec 16, 2025
-
CEO of Samsung Epis Holdings and Samsung Bioepis
Life Summary
Kim Kyung-ah is CEO of Samsung Epis Holdings and CEO of Samsung Bioepis.
She oversees biosimilar research and development while seeking to expand into new drug development.
She was born in 1968.
She graduated from the College of Pharmacy at Seoul National University and earned a master’s degree in pharmacy from Seoul National University Graduate School. She received a Ph.D. in toxicology from the Johns Hopkins University Graduate School in the United States.
She began her career at the U.S. new drug development company HighTech.
After working at the biotech company Nuvelo, she served as a researcher at the life sciences company Stemline.
She joined Samsung Advanced Institute of Technology as head of the Bio New Drug Group and worked as an executive in charge of the Biopharmaceutical Lab and the Life Sciences Research Center.
She later moved to Samsung Bioepis, where she served as head of the Development Division before being appointed CEO in 2024.
She is the first female professional manager (CEO) in the Samsung Group.
She also serves as the inaugural CEO of Samsung Epis Holdings, a newly established bio investment holding company created following the spin-off from Samsung Biologics.
#KimKyungah #SamsungBioepis #SamsungEpisHoldings #biopharmaceuticals #biosimilars #newdrugdevelopment #femaleCEO #SamsungGroup #biotechnology #pharmaceuticalindustry
She oversees biosimilar research and development while seeking to expand into new drug development.
She was born in 1968.
She graduated from the College of Pharmacy at Seoul National University and earned a master’s degree in pharmacy from Seoul National University Graduate School. She received a Ph.D. in toxicology from the Johns Hopkins University Graduate School in the United States.
She began her career at the U.S. new drug development company HighTech.
After working at the biotech company Nuvelo, she served as a researcher at the life sciences company Stemline.
She joined Samsung Advanced Institute of Technology as head of the Bio New Drug Group and worked as an executive in charge of the Biopharmaceutical Lab and the Life Sciences Research Center.
She later moved to Samsung Bioepis, where she served as head of the Development Division before being appointed CEO in 2024.
She is the first female professional manager (CEO) in the Samsung Group.
She also serves as the inaugural CEO of Samsung Epis Holdings, a newly established bio investment holding company created following the spin-off from Samsung Biologics.
#KimKyungah #SamsungBioepis #SamsungEpisHoldings #biopharmaceuticals #biosimilars #newdrugdevelopment #femaleCEO #SamsungGroup #biotechnology #pharmaceuticalindustry